OncoMatch/Clinical Trials/NCT07333274
Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
Is NCT07333274 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Nimotuzumab for head & neck squamous cell carcinoma.
Treatment: Nimotuzumab — This is an open-label, prospective, randomized, Phase III, international multicenter clinical study to compare radiotherapy plus nimotuzumab versus radiotherapy alone in platinum-ineligible patients with locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC),
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Biomarker criteria
Required: EGFR testing required if tissue available (testing required; no eligibility threshold specified)
Provide tumor tissue, whenever possible, for EGFR testing
Required: HPV testing required for oropharyngeal cancer if tissue available (testing required; no eligibility threshold specified)
for oropharyngeal cancer, provide tissue for HPV/p16 testing if feasible
Disease stage
Required: Stage III, IVA, IVB
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: pd-1 inhibitor
Exception: within 4 weeks prior to enrollment
Cannot have received: egfr monoclonal antibody
Exception: within 4 weeks prior to enrollment
Cannot have received: egfr tyrosine kinase inhibitor
Exception: within 4 weeks prior to enrollment
Cannot have received: anti-angiogenic agent
Exception: within 4 weeks prior to enrollment
Lab requirements
Blood counts
wbc ≥4×10^9/l; absolute neutrophil count ≥1.5×10^9/l; platelets ≥100×10^9/l; hemoglobin ≥90 g/l
Kidney function
serum creatinine ≤1.5×uln or crcl ≥60 ml/min (cockcroft-gault)
Liver function
total bilirubin ≤1.5×uln; ast ≤2.5×uln; alt ≤2.5×uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07333274 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior pd-1 inhibitor, egfr monoclonal antibody, egfr tyrosine kinase inhibitor disqualifies patients from enrollment.
Does this trial require EGFR?
Yes, EGFR testing required if tissue available is a required biomarker for enrollment.
Does this trial require HPV?
Yes, HPV testing required for oropharyngeal cancer if tissue available is a required biomarker for enrollment.
What disease stage is eligible?
Stage III or IVA or IVB is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify